New MRI technique aims to spot hidden spinal cord lesions in MS
NCT ID NCT04819737
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing a new MRI technique called AMIRA to see if it can find spinal cord lesions in people with multiple sclerosis better than standard MRI. Ten participants will undergo both the new and standard scans. The goal is to improve how doctors detect and monitor spinal cord damage in MS.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better detection of spinal cord damage in MS, helping doctors diagnose and monitor the disease more accurately.
- What could go wrong
- This is a very small pilot study with only 10 participants, so results may not apply to everyone. The new MRI technique might not prove more useful than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2022
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of multiple sclerosis according to established international criteria * Steroid free period: \> 4 weeks * Participation in the Swiss MS Cohort (SMSC) study Exclusion Criteria: * . History of severe (other) neurological, internal or psychiatric disease with SC affection * MRI-related exclusion criteria (questionnaire): 1. Paramagnetic and/or superparamagnetic foreign objects in the body (especially when located close to the SC) 2. Pacemaker 3. Claustrophobia 4. Pregnancy, lactation 5. Known hypersensitivity to gadolinium-based contrast media
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple sclerosis (MS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital Basel, Department of Neurology
RECRUITINGBasel, 4031, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame stubborn multiple sclerosis?
- Could a gentle zapping of the brain ease MS fatigue and brain fog?
- Engineered immune cells take aim at autoimmune diseases
- Can an extra shot boost COVID protection in autoimmune patients?
- CAR-T therapy targets autoimmune diseases, but trial never started
- Nurse-Led video calls aim to empower MS patients